Dossier: Parkinson's disease
Therapy of behavioral disorders in Parkinson's disease

https://doi.org/10.1016/S0753-3322(99)80081-XGet rights and content

Summary

Behavioral disturbances in Parkinson's disease (PD) are a common source of disability to both patients and their families, but there is a considerable controversy regarding their frequency and their neuropathological and neurochemical bases. Since they are so common, the disorders associated with PD should be well recognized, and proper management by neurologists is required. The most frequent behavioral disturbances encountered in patients with PD are depression, anxiety, cognitive impairment and dementia. Also frequent are sleep disorders such as sleep fragmentation, REM sleep behavior disorder, insomnia and altered dreaming. The most troublesome situations come from drug-induced psychiatric states, such as delusional states, hallucinations, paranoid ideation, delirium, and confusion. The treatment of these behaviors is reviewed here.

References (56)

  • FordB et al.

    Risperidone in PD

    Lancet

    (1994)
  • GrossG et al.

    Trimipramine: pharmacological reevaluation and comparison with clozapine

    Neuropharmacol

    (1991)
  • LivingstonMG

    Risperidone

    Lancet

    (1994)
  • MecoG et al.

    Risperidone for hallucinations in L-dopa-treated PD patients

    Lancet

    (1994)
  • BorisonRL et al.

    Risperidone: clinical safety and efficacy in schizophrenia

    Psychopharmacol Bull

    (1992)
  • BorisonRL

    Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics

    J Clin Psychopharmacol

    (1995)
  • BouchardRH et al.

    Fluoxetine and extrapyramidal side effects

    Am J Psychiatry

    (1989)
  • FactorSA et al.

    Clozapine: a 2-year open trial in PD patients with psychosis

    Neurology

    (1994)
  • FactorSA et al.

    Clozapine prevents recurrence of psychosis in Parkinson's disease

    Mov Disord

    (1992)
  • FactorSA et al.

    The emerging role of clozapine in the treatment of movement disorders

    Mov Disord

    (1997)
  • FernandezHH et al.

    Clozapine for dopaniergic-induced paraphilias in Parkinson's disease

    Mov Disord

    (1998)
  • FriedmanJH et al.

    Clozapine in the treatment of psychosis in PD

    Neurology

    (1989)
  • FriedmanJH et al.

    Substituting clozapine for olanzapine in psychiatrically stable Parkinson's disease patients: results of an open-label pilot study

    Clin Neuropharmacol

    (1998)
  • FriedmanJH

    Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease

    Neurology

    (1998)
  • GerlachJ et al.

    Motor and mental side effects of clozapine

    J Clin Psychiatry

    (1994)
  • GoetzCG et al.

    Risk factors for nursing home placement in advanced Parkinson's disease

    Neurology

    (1993)
  • GoetzCG et al.

    Early dopaminergic drug-induced hallucinations in parkinsonian patients

    Neurology

    (1998)
  • GoodwinFK

    Psychiatric side effects of L-dopa in man

    JAMA

    (1971)
  • Jansen SteurENH

    Increase of Parkinson disability after fluoxetine medication

    Neurology

    (1993)
  • Jiménez-JiménezFJ et al.

    Parkinsonism exacerbated by paroxetine

    Neurology

    (1994)
  • Jiménez-JiménezFJ et al.

    Olanzapine can worsen parkinsonism

    Neurology

    (1998)
  • Juul-PovlsenU et al.

    Tolerability and therapeutic effect of clozapine: a retrospective investigation of 216 patients, treated with clozapine for up to 12 years

    Acta Psychiatr Scand

    (1985)
  • KruppP et al.

    Clozapine-associated agranulocytosis: risk and aetiology

    Br J Psychiatry

    (1992)
  • LangAE et al.

    Remoxipride in Parkinson's disease: differential response in patients with dyskinesias/fluctuations vs. psychosis

    Ann Neurol

    (1993)
  • LewMF et al.

    Clozapine treatment of parkinsonism with psychosis

    J Am Geriatr Soc

    (1993)
  • LipinskiJF et al.

    Fluoxetine-induced akathisia: clinical and theoretical implications

    J Clin Psychiatry

    (1989)
  • MegensAAHP et al.

    Survey on the pharmacodynamics of the new antipsychotic risperidone

    Psychopharmacol

    (1994)
  • MeltzerHY et al.

    Melperone and clozapine: neuroendocrine effects of typical neuroleptic drugs

    Acta Psychiatr Scand

    (1989)
  • Cited by (12)

    • Sleep disorders in Parkinson's disease

      2004, Clinical Cornerstone
    • The pharmacostrategy of treating sleep disorders in parkinsonism

      2006, Sleep and Sleep Disorders: A Neuropsychopharmacological Approach
    View all citing articles on Scopus
    View full text